In high transmission setting, new infection after treatment have been very uncommon. in India, particularly in the northeast along the Myanmar border, where artesunate/sulfadoxine-pyrimethamine combinations are being discontinued, there have been excellent responses to artesunate/mefloquine, artesunate/amodiaquine, and dihydroartemisinin/piperaquine.